With this transaction, Intersurgical will integrate the Acute Care and Interventional Urology product ranges, technical ...

Teleflex is splitting its business into two independently traded entities, with a completion date set for mid-2026. The company’s urology, acute care, and OEM businesses will be grouped under Teleflex ...

Teleflex stock (NYSE: TFX), best known for its single-use medical devices for common diagnostic and therapeutic procedures, has seen a 31% fall this year, underperforming the broader S&P500 index, ...

Teleflex is selling its acute care, interventional urology, and original equipment manufacturer (OEM) businesses in two separate deals totalling over $2bn as part of the company’s broader portfolio ...

Teleflex (TFX) has agreed to sell its acute care, interventional urology and OEM businesses to two buyers for a combined $2.03 billion in cash, subject to adjustments. Intersurgical will acquire the ...

Teleflex may be enjoying improved profits and sales. But it will still lay off workers and close plants as it restructures in the face of what top executive Benson F. Smith describes as "continuing ...

Teleflex Incorporated presented new clinical data at the 2025 American Urological Association Annual Meeting, highlighting the UroLift™ System as a leading minimally invasive treatment for benign ...

In the last three months, 5 analysts have published ratings on Teleflex (NYSE:TFX), offering a diverse range of perspectives from bullish to bearish. The following table provides a quick overview of ...

Teleflex is inking a $650 million deal to acquire Palette Life Sciences, the maker of urologic spacer implants and tissue bulking products. The agreement includes $600 million in upfront cash, plus ...

The stock price of Teleflex, best known for its single-use medical devices for common diagnostic and therapeutic procedures, has seen a decline of 12% over the last month, while it was down over 4% ...